Cerevel Therapeutics Holdings, Inc. – NASDAQ:CERE

Financial Health
0
1
2
3
4
5
6
7
8
9

Cerevel Therapeutics Holdings stock price monthly change

-1.80%
month

Cerevel Therapeutics Holdings stock price quarterly change

-4.41%
quarter

Cerevel Therapeutics Holdings stock price yearly change

+17.97%
year

Cerevel Therapeutics Holdings key metrics

Market Cap
8.19B
Enterprise value
4.15B
P/E
-11.2
EV/Sales
N/A
EV/EBITDA
-12.28
Price/Sales
N/A
Price/Book
7.52
PEG ratio
0.27
EPS
-2.73
Revenue
N/A
EBITDA
-456.02M
Income
-460.46M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Cerevel Therapeutics Holdings stock price history

Cerevel Therapeutics Holdings stock forecast

Cerevel Therapeutics Holdings financial statements

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE): Profit margin
Jun 2023 0 -99.53M
Sep 2023 0 -96.36M
Dec 2023 8.24M -132.66M -1608.78%
Mar 2024 0 -131.91M
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE): Analyst Estimates
Dec 2023 8.24M -132.66M -1608.78%
Mar 2024 0 -131.91M
Sep 2025 8.24M -132.69M -1609.23%
Oct 2025 0 -138.02M
  • Analysts Price target

  • Financials & Ratios estimates

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE): Earnings per share (EPS)
2024-02-20 -0.59 -0.76
2024-03-20 -0.58 -0.59
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE): Debt to assets
Jun 2023 894353000 543.85M 60.81%
Sep 2023 821962000 549M 66.79%
Dec 2023 1243298000 569.55M 45.81%
Mar 2024 1127343000 562.88M 49.93%
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE): Cash Flow
Jun 2023 -77.32M 61.75M 37.61M
Sep 2023 -72.63M 51.39M 1.19M
Dec 2023 -97.42M -150.20M 508.37M
Mar 2024 -119.66M 19.16M 4.47M

Cerevel Therapeutics Holdings alternative data

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE): Employee count
Aug 2023 319
Sep 2023 322
Oct 2023 322
Nov 2023 322
Dec 2023 321
Jan 2024 321
Feb 2024 321
Mar 2024 334
Apr 2024 334
May 2024 334
Jun 2024 355
Jul 2024 355

Cerevel Therapeutics Holdings other data

87.49% +3.60%
of CERE is owned by hedge funds
129.74M +5.59M
shares is hold by hedge funds

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE): Insider trades (number of shares)
Period Buy Sel
Aug 2023 105737 0
Sep 2023 0 50000
Oct 2023 17316964 0
Nov 2023 0 180130
Dec 2023 0 104465
Jan 2024 0 50000
Feb 2024 0 54667
Mar 2024 0 50000
Apr 2024 0 50000
May 2024 0 50000
Jun 2024 0 50000
Jul 2024 0 25000
Transaction Date Insider Security Shares Price per share Total value Source
Option
COLES N ANTHONY director Common Stock 25,000 $3.5 $87,500
Sale
COLES N ANTHONY director Common Stock 25,000 $41.18 $1,029,525
Option
COLES N ANTHONY director Stock Option (Right to Buy) 25,000 $3.5 $87,500
Option
COLES N ANTHONY director Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
COLES N ANTHONY director Common Stock 50,000 $3.5 $175,000
Sale
COLES N ANTHONY director Common Stock 50,000 $40.61 $2,030,500
Option
COLES N ANTHONY director Stock Option (Right to Buy) 50,000 $3.5 $175,000
Option
COLES N ANTHONY director Common Stock 50,000 $3.5 $175,000
Sale
COLES N ANTHONY director Common Stock 50,000 $42.1 $2,105,150
Option
COLES N ANTHONY director Stock Option (Right to Buy) 50,000 $3.5 $175,000
Insider Compensation
Dr. N. Anthony Coles Jr., M.P.H. (1960) Chief Executive Officer & Executive Chairman $1,240,000
Dr. John J. Renger Ph.D. (1969) Chief Scientific Officer $945,080
Ms. Kathleen Tregoning M.A. (1971) Chief Corporation Affairs Officer
$600,790
Thursday, 1 August 2024
prnewswire.com
Monday, 1 July 2024
accesswire.com
Sunday, 30 June 2024
accesswire.com
Saturday, 29 June 2024
accesswire.com
Friday, 28 June 2024
accesswire.com
Thursday, 27 June 2024
accesswire.com
Wednesday, 26 June 2024
accesswire.com
Tuesday, 25 June 2024
accesswire.com
accesswire.com
globenewswire.com
Monday, 24 June 2024
accesswire.com
accesswire.com
Sunday, 23 June 2024
accesswire.com
Saturday, 22 June 2024
accesswire.com
globenewswire.com
Friday, 21 June 2024
accesswire.com
accesswire.com
Thursday, 20 June 2024
accesswire.com
accesswire.com
prnewswire.com
globenewswire.com
Wednesday, 19 June 2024
accesswire.com
accesswire.com
Tuesday, 18 June 2024
accesswire.com
businesswire.com
globenewswire.com
Monday, 17 June 2024
accesswire.com
Friday, 14 June 2024
accesswire.com
Thursday, 13 June 2024
accesswire.com
accesswire.com
  • When is Cerevel Therapeutics Holdings's next earnings date?

    Unfortunately, Cerevel Therapeutics Holdings's (CERE) next earnings date is currently unknown.

  • Does Cerevel Therapeutics Holdings pay dividends?

    No, Cerevel Therapeutics Holdings does not pay dividends.

  • How much money does Cerevel Therapeutics Holdings make?

    Cerevel Therapeutics Holdings has a market capitalization of 8.19B. Cerevel Therapeutics Holdings made a loss 432.84M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.

  • What is Cerevel Therapeutics Holdings's stock symbol?

    Cerevel Therapeutics Holdings, Inc. is traded on the NASDAQ under the ticker symbol "CERE".

  • What is Cerevel Therapeutics Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Cerevel Therapeutics Holdings?

    Shares of Cerevel Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Cerevel Therapeutics Holdings's key executives?

    Cerevel Therapeutics Holdings's management team includes the following people:

    • Dr. N. Anthony Coles Jr., M.P.H. Chief Executive Officer & Executive Chairman(age: 65, pay: $1,240,000)
    • Dr. John J. Renger Ph.D. Chief Scientific Officer(age: 56, pay: $945,080)
    • Ms. Kathleen Tregoning M.A. Chief Corporation Affairs Officer(age: 54, pay: $600,790)
  • How many employees does Cerevel Therapeutics Holdings have?

    As Jul 2024, Cerevel Therapeutics Holdings employs 355 workers, which is 6% more then previous quarter.

  • When Cerevel Therapeutics Holdings went public?

    Cerevel Therapeutics Holdings, Inc. is publicly traded company for more then 5 years since IPO on 30 Jul 2020.

  • What is Cerevel Therapeutics Holdings's official website?

    The official website for Cerevel Therapeutics Holdings is cerevel.com.

  • Where are Cerevel Therapeutics Holdings's headquarters?

    Cerevel Therapeutics Holdings is headquartered at 222 Jacobs Street, Cambridge, MA.

  • How can i contact Cerevel Therapeutics Holdings?

    Cerevel Therapeutics Holdings's mailing address is 222 Jacobs Street, Cambridge, MA and company can be reached via phone at +84 43042048.

Cerevel Therapeutics Holdings company profile:

Cerevel Therapeutics Holdings, Inc.

cerevel.com
Exchange:

NASDAQ

Full time employees:

355

Industry:

Biotechnology

Sector:

Healthcare

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

222 Jacobs Street
Cambridge, MA 02141

CIK: 0001805387
ISIN: US15678U1280
CUSIP: 15678U128